Navigation Links
Novel anti-malarial drug candidate found by UT Southwestern researchers
Date:5/25/2010

DALLAS May 25, 2010 As part of a multicenter study, UT Southwestern Medical Center researchers have identified a series of chemical compounds that might serve as starting points for the identification of new classes of anti-malarial drugs.

"Malaria remains one of the most globally significant infectious diseases that we face," said Dr. Margaret Phillips, professor of pharmacology at UT Southwestern and one of the senior authors of the study, which appears in the May 20 issue of Nature. Malaria affects about 40 percent of the world's population and kills about a million people a year, she said. The parasite that causes the disease is spread by mosquito bites.

Drugs are the mainstay of malaria treatment, yet the malaria parasite is notorious for developing drug resistance, which compromises current chemotherapy.

"Novel chemical compounds with anti-malarial activity represent a potent tool in the process of developing new drugs to treat this disease," Dr. Phillips said.

The study, done in collaboration with Dr. Kiplin Guy of St. Jude Children's Research Hospital in Memphis and other researchers, started with a "library" of 309,474 chemical compounds.

The researchers used a technique called high throughput screening, which allowed them to test thousands of compounds quickly to identify those with anti-malarial action.

"In addition, publishing the full set of identified compounds will maximize the chances for the most-promising candidates to move into large-scale drug development programs," Dr. Phillips said.

The screen identified 1,152 compounds that killed the parasite. The researchers then followed up with further tests to determine the mechanism of action of the identified compounds, where possible.

Dr. Phillips and her group tested whether any of the identified compounds killed malaria parasites by inhibiting an enzyme necessary to make pyrimidine, an intermediate molecule for creating DNA. She discovered that three of the library's compounds with anti-malarial activity blocked this enzyme. Two of those had similar chemical structures to a class of known compounds that she and her colleagues have been studying for possible drug development. The third compound previously was not known to target the enzyme.

"It looked very different from anything we knew about before," she said.

Having a variety of anti-malarial drugs with different chemical structures and modes of action is important because different types of drugs are given together to slow the parasite from developing resistance, Dr. Phillips said.

In all, the researchers from the various centers found 172 compounds that are "reasonable starting points" for development of new types of drugs.

"We call the identified candidates 'hits,' but if any of them are going to become drugs, they're going to have to undergo chemical modification," Dr. Phillips said. "For instance, they may need to be altered chemically to enter the cell more easily, or to improve their pharmacology so they will be more effective in people."


'/>"/>

Contact: Aline McKenzie
aline.mckenzie@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
2. Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
3. Third European Novel Food Approval Received by Tahitian Noni International
4. Novel nanoparticles prevent radiation damage
5. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
6. Novel Method Eyed for Normalizing Blood Sugar
7. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
8. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
9. Novel medical home program for pediatric patients, families cuts ER visits in half
10. Novel stroke treatment passes safety stage of UCI-led clinical trial
11. Reovirus may be a novel approach to prostate cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
Breaking Medicine Technology: